Notably, Menin inhibitors are in clinical trials for the treatment of relapsed or refractory NPM1–mutated acute leukemia and acute leukemia with MLLr and have shown on-target effects, tolerable toxicity, and promising clinical activity (1, 8). Here, NPM1 is linked to acute leukemia.